Quantcast
Home > Quotes > CHRS
CHRS

Coherus BioSciences, Inc. Common Stock (CHRS) Quote & Summary Data

$17.78
*  
0.74
4%
Get CHRS Alerts
*Delayed - data as of Jul. 17, 2019  -  Find a broker to begin trading CHRS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CHRS After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 17.56 / $ 17.92
Today's High / Low
$ 18.525 / $ 17.76
Share Volume
507,762
50 Day Avg. Daily Volume
1,129,936
Previous Close
$ 18.52
52 Week High / Low
$ 23.43 / $ 8.32
Market Cap
1,233,406,725
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
507,762
50 Day Avg. Daily Volume:
1,129,936

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.76

Trading Range

The current last sale of $17.78 is 113.70% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 18.525 $ 23.43
 Low: $ 17.76 $ 8.32

Company Description (as filed with the SEC)

We are a commercial-stage biotherapeutics company focused on the global biosimilar market. Biosimilars are a class of protein-based therapeutics with high similarity to approved originator products on the basis of various structural, physicochemical and biological properties, as well as in terms of safety and efficacy. Our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production, and clinical-regulatory development. On September 25, 2018, we received regulatory approval for the marketing of UDENYCA(TM) (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission. On November 2, 2018, the U.S. Food and Drug Administration ("FDA") approved our biologics license application ("BLA") for UDENYCA(TM) as a biosimilar to Neulasta. We initiated U.S.  ... More ...  



Risk Grade

Where does CHRS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 18.46
Open Date:
Jul. 17, 2019
Close Price:
$ 17.78
Close Date:
Jul. 17, 2019


Consensus Recommendation

Analyst Info